Press Releases

Press Releases

Company’s ultra-sensitive platform continues to facilitate important advances that harness biomarkers to identify, monitor and validate treatment pathways for Multiple Sclerosis (MS) | September 10, 2020
September 10, 2020 09:00 AM Eastern Daylight Time
August 07, 2020
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the pricing of its previously announced underwritten public offering of 2,651,10
August 06, 2020
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it has commenced an underwritten public offering of its common stock.

This website uses cookies. By continuing to use this website you are acknowledging and agree with our cookie policy.

AgreeLearn more